Research programme: Fabry's disease therapeutics - Evotec AG/Shire
Latest Information Update: 17 Oct 2014
At a glance
- Originator Evotec AG; Shire
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Fabry's disease
Most Recent Events
- 12 Aug 2014 Early research in Fabry's disease in Ireland (unspecified route) before August 2014
- 12 Aug 2014 Early research in Fabry's disease in Germany (unspecified route) before August 2014